Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Health CanadaRegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 5, 2026

HC comparative bioavailability standards

Comparative Bioavailability Standards: Formulations Used for Systemic Effects

Current edition

Adopted 2012/12/08, revised 2018/06/08, effective 2018/09/01

About this standard

Sets the pharmacokinetic acceptance standards for bioequivalence and comparative bioavailability, with special standards for modified-release, critical dose and highly variable drugs. Standards for immediate-release products were replaced by ICH M13A from December 27, 2025.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube